The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The National Stock Exchange (NSE) has asked Supriya Lifescience to clarify certain matters related to its financial results for the quarter ended 31-March-2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The specific point raised is that segment details were not submitted along with the results. The company has not yet responded, and its reply is awaited. This is a procedural clarification request and not a penalty or enforcement action. Investors should watch for the company's response, which may simply provide the missing segment-wise breakdown.
This is a routine compliance query and is unlikely to materially affect the stock. However, persistent non-compliance with disclosure norms could attract regulatory scrutiny, so investors should monitor the company's response and any follow-up action from the exchange.